Pay in 4 interest-free payments of $5.30 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Why this trial matters: First global Phase III success in a disease with no approved targeted therapy Could change management of systemic symptoms and glandular dysfunction Gene Therapy Phase III in Epidermolysis Bullosa Shows Healing Benefit A Phase III gene therapy trial for epidermolysis bullosa (EB) demonstrated significantly better wound healing, less pain, and reduced itching compared with standard care, and the therapy earned FDA approval in 2025 a major advance for this previously untreatable genetic skin disorder
Indeed, many original investigations, summarized in later review [4], indicated that LC supplementation lasting up to 4 weeks, neither increase fat oxidation nor improve performance during prolonged exercises
55,56 These findings prompted regulatory safety communications and heightened surveillance regarding pancreatic safety
SASP, senescence-associated secretory phenotype
The primary behavioral study performed was the water maze test that consisted of a circular apparatus painted black and filled with water to a depth of 26 cm
